

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

PARACETAMOL OVERDOSE

Ingested over a period of one hour or less – presenting more than 24 hours after acute ingestion

Patients < 16 years

NHS Borders

This care pathway includes the Scottish and Newcastle Antiemetic Pretreatment (SNAP) based regimen for acetylcysteine and is **ONLY** for use in the Emergency department or ward 15, Borders General Hospital.

This version is not available on TOXBASE. For advice contact the oncall toxicologist at the RIE (Monday –Friday 9am-5pm) or the National Poisons Information Service (NPIS) out of hours.

There are 5 different care pathway documents for paracetamol overdose in patients <16 years, please ensure the correct document is used.

Review January 2022

Patients < 16 years PARACETAMOL OVERDOSE – more than 24HOURS

ED presentation date..... Time.....

Ward admission date..... Time.....

Admitting Consultant.....

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

Expected length of stay: approx 24 hours

To be initiated once a PARACETAMOL overdose is suspected

Ingested over a period of one hour or less – Presenting more than 24 hours after acute ingestion

Print name	Designation	Initials	Signature	Date
			- 9	
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				

<u>STAFF:</u>

Should be completed in addition to the Clerking notes, PEWS observation chart, infusion charts, prescription & administration record.

Patients < 16 years **PARACETAMOL OVERDOSE – more than 24 HOURS** Date:

Clinical area: ED \Box Ward \Box

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

			Initials & time
SUMMARY			
Ingestion date	Was para	acetamol bought for overdose: Yes \Box	No 🗆
Ingestion time	Total par	acetamol ingested	q
List all the drug(s) ingested (including prescribed)	-	weight	
	CALCUL The amo	ATE unt of paracetamol ingested	mg / kg
	Notes	For obese patients weighing more than toxic dose in mg/kg should be calculated u rather than the patient's actual weight.	• ·
Alcohol ingested? Yes □No□			
Approx units		The National Poisons Information Service a the child's actual weight should be used calculating both the toxic dose and the ace dose, up to a maximum of 110kg .	for
		For pregnant patients the toxic dose in m be calculated using the patient's pre-pregn	

This document represents the care expected for a majority of your patients. It is expected that some patients will need care other than that noted. This is referred to as a 'Variance' and should be noted as 'Var' in the appropriate space & explained fully on the 'Varience' sheet, page .

Clinicians are free to exercise their own professional judgements as appropriate.

However, any alteration to practice noted in this document should be noted as a 'Variance' in notes.

NHS BORDERS	ADDRESSOGRAPH, or
Patients < 16 years	ADDRESSOGRAPH, OF
PARACETAMOL OVERDOSE – more than 24HOURS	Name:
Date:	DoB:
	Hospital number:
Clinical area: ED 🔲 Ward 🗆	CHI:

Ingested over a period of one hour or less-presenting more than 24 hours after acute ingestion

Wait for blood results before starting acetylcysteine unless the patient is clearly jaundiced or has hepatic tenderness. There is no evidence that treating with acetylcysteine before blood tests are available confers benefit or that delaying treatment for a short period while waiting for blood results worsens prognosis in patients who present more than 24 hours after overdose

IMMEDIATE ASSESSMENT AND MANAGEMENT	
Assessment of hepatic injury	Initial &
Clinical features of hepatic injury (jaundice or hepatic tenderness) Yes	time
• If Yes,	
START ACETYLCYSTEINE IMMEDIATELY DO NOT WAIT FOR BLOOD RESULTS	
(Refer to SNAP based dosage on initiation/prescription chart)	
• If No.	
Wait for blood results to determine if acetylcysteine is required	
Blood sampling	
• Obtain urgent blood samples for paracetamol concentration, U&Es, LFTs, GGT,	
FBC, INR	
ON RECEIPT OF BLOOD RESULTS:	
• Date, time and blood results documented on page	
If treatment has not been initiated START acetylcysteine if:	
• Paracetamol concentration is detectable (5mg/L or more) OR	
• INR is greater than 1.3 (in the absence of another cause, e.g. warfarin) OR	
 ALT is above the upper limit of normal (50 U/L) 	
Patients with a chronically elevated ALT (e.g. chronic liver disease), may not require	-
acetylcysteine treatment if the ALT and INR have not significantly changed from previously	
documented values. These cases should be discussed with the National Poisons Information	
Service (NPIS) Tel 13448920111	
Haemodialysis may be indicated alongside acetylcysteine if the patient has a very high	
paracetamol concentration and an elevated lactate. For advice contact toxicologist or NPIS out	
of hours	
The patient is considered not to be at risk of liver toxicity if:	
 Paracetamol concentration is not detectable (less than 5mg/L) AND 	
INR is 1.3 or less AND	
 ALT is within normal range (50 U/L or less) AND 	
 The patient is asymptomatic with no clinical features suggesting liver damage 	
 If these criteria are met the acetylcysteine is not required 	
If these criteria are met and acetylcysteine has been started it can be discontinued	
Assessment of renal function	
 If acetycysteine is not required and the creatinine is normal the patient can be 	
discharged. Provide the patient with a 'Patient Information Sheet' (available on	
TOXBASE)	
• If acetylcysteine is not required and the creatinine is abnormal the patient should remain	
in hospital for monitoring of renal function and if require, treated conventionally.	
If treatment with acetylcysteine is not indicated and further blood tests are not required, go to 'Su	bsequent
Management & Discharge' (pg 9)	

Clinical area: ED \Box Ward \Box

Patients < 16 years
PARACETAMOL OVERDOSE – more than 24HOURS
Date:

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

Please tick boxes as appropriate and initial/ time in conjunction with inpatient record

Assessment blood results	Repeat blood results (if required)
Date/Time of sample	Date/Time of sample
Urea	Urea
Sodium	Sodium
Potassium	Potassium
Creatinine	Creatinine
Bilirubin	Bilirubin
ALT	ALT
AlkPhos	AlkPhos
GGT	GGT
Albumin	Albumin
Hb	Hb
MCV	MCV
WCC	WCC
Platelets	Platelets
INR	INR
Plasma paracetamol concentration Athours post ingestion Glucose	Plasma paracetamol concentration Athours post ingestion Glucose
pH	pH
Lactate	Lactate
HCO3	HCO3
BE	BE
Other	Other
Initials date/time	Initials date/time

NHS	BOR	DERS
-----	-----	------

Patients < 16 years **PARACETAMOL OVERDOSE –more than 24HOURS** Date:

Clinical area: ED \Box Ward \Box

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

REACTION to acetylcysteine			COMPLICATIONS of paracetamol ingestion			
None	□ Wheez	9		Abnormal liver function Encephalopathy]	
Flushing	□ Hypote	nsion Other		Acute kidney injury]	
Vomiting	□ Specify			Hypoglycaemia D Other D]	
Rash				Acidosis		
Date and time of reaction		Initial		Date and time of reaction Initial		
 hypotension, angio Reactions can be m salbutamol if there Restart the infusio Previous reaction is 	hay cause a bedema, bro hanaged by e is brochos o n once the s NOT a con	ochospasm and stopping the im pasm and ondar reaction has re ntra-indication t	vomiti fusion nsetro solvec o N-ac	in 2% of cases with this protocol. Flushing, pruritus, rash, ng are most common Consider chlorphenamine for flushing/itch, nebulised n if there are GI effects. I at half the rate to completion of infusion etylcysteine and cases should receive treatment if indicated. his protocol compared to standardregimes		
Ondansetron oral or IV s	low inject	ion (nausea ar	nd vor	niting) – Age 6 months -16 years		
Body weight				Dose		
Up to 10kg				2mg three times a day		
10 -40kg				4mg three times a day		
41kg and above				8mg three times a day		
Chlorphenamine oral (ra	sh and itc	ר)				
Age				Dose		
1-23 months				1mg twice per day		
2-5 years				1mg 4-6 hourly maximum 6mg per day		
6-11 years				2mg 4-6 hourly maximum 12mg per day		
12-16 years				4mg 4-6 hourly maximum 24mg per day		
Chlorphenamine IV inject	tion (rash	or itch)				
Age				Dose		
1-5 months				250 microgrames/kg, maximum 4 times daily		
6 months-5years				2.5mg, maximum four times daily		
6-11 years				5mg, maximum four times daily		
12-16 years				10mg, maximum four times daily		

Patients < 16 years
PARACETAMOL OVERDOSE – more than 24 HOURS
Date:

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

Clinical area: ED \Box Ward \Box

		REVIEW OF TR	EATMENT WITH A	CETYLCYSTEINE		
• 10 ho	our bloods: n		fore the end of 2 nd in			Initial/time
			ETAMOL CONCENTRA			
• 10 ho	our bloods: o	btain usually 2 hou	rs before the end of 2	2 nd infusion		
 Blood 	d results docu	imented in table be	elow			
• Resu	Its reviewed	by Advanced Nurs	e Practitioner/senior	medical staff		
<u>10 hour bloo</u>						
Crite		• •	ysteine after 2 nd infus	ion are:		
	INR 1.3 or					
		nan 100 U/L AND				
			e admission measure	ment AND		
			n less than 20mg/L			
			acetylcysteine on pag	-		
		ULD REMAIN IN HO	JSPITAL FOR 20 HOUI	R BLOOD SAMPLING s	ee page a	5
Blood res	suits					
	Pre	10 hour bloods	20 hour bloods	End of extended	End	of extended
	<u>Treatment</u>			<u>treatment</u> bloods	treat	<u>ment bloods</u>
Notes		Blood samples 2 hours before the	Blood samples 8 hours	Blood samples 2 hours before the		samples 2 hours
		end of infusion 2	after the end of infusion 2	end of extended infusion	before extende	the end of ed infusion
		Date/time taken Initial	Date/time taken Initial	Date/time taken Initial	Date, Initia	/time taken
Urea					Ind	·
Sodium						
Potassium	*					
pH/HCO3/BE						
Creatinine	*					I
eGFR						
Bilirubin						
ALT	*					
Alk. Phos						
Hb						
WCC						
Platelets						
INR	*					
Paracetamol	*					
Reviewed by		Initial	Initial	Initial	Initia	
Decision		Continue / stop	Restart / continue / stop	Continue / stop	Cont	inue / stop

Patients < 16 years
PARACETAMOL OVERDOSE -more than 24 HOURS
Date:

Clinical area: ED \Box Ward \Box

ADDRESSOGRAPH, or

Name: DoB: Hospital number: CHI:

END OF TREATMENT WITH ACETYLCYSTEINE	
If criteria for discontinuing acetylcysteine at the end of the second infusion are met	
Discontinue acetylcysteine once infusion 2 is <u>complete</u>	
Acetylcysteine discontinued at	
If Creatinine is abnormal lor is 10% greater than presentation and the criteria for discontinuing acetylcys	
are met, further acetylcysteine is not required but renal function should be monitored as an inpatient. Re	echeck
12 hours later	
once the criteria for discontinuing acetylcysteine are met, 2 nd infusion is complete and further blood sam	npling is
not required go to Stage 4 'Subsequent Management & Discharge' (page 9)	
If criteria for discontinuing acetylcysteine at the end of infusion 2 are NOT met:	Initial & time
• Continue acetylcysteine treatment at the dose and infusion rate of infusion 2	unio
 Obtain discharge bloods (U&Es, LFTs, FBC &INR) 2 hours befopre the end of the extra bag 	
of acetylcysteine (20 hour bloods)	
Discharge (20 hour) bloods due at Discharge (20 hour) bloods obtained at	
Discharge (20 hour) bloods documented in table on page 7	
Results reviewed by Advanced Nurse Practitioner/senior medical staff	
Discharge 20 hour bloods review	
Extended or restarted acetylcysteine is indicated if:	
INR is greater than 1.3 OR	
ALT has more than doubled from admission bloods	
ALT is 100 U/L or more This applies to both patients who stopped treatment after 2nd infusion AND patients who continued	
treatment after 2 nd infusion	
If criteria for extended acetylcysteine are not met, no further acetylcysteine is not required	
 If creatinine is abnormal or is 10% greater than at presentation, further acetylcysteine is not required 	uired but
renal function should be monitored as an inpatient. Recheck in 12 hours later.	
	Initial &
Decision	
Decision	Initial &
	Initial &
 Decision If further treatment or blood sampling is not required go to 'Subsequent Management & 	Initial &
 Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) 	Initial &
 Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team 	Initial &
 Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team 	Initial &
 Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team If extended or restarted acetylcysteine is indicated follow advice below 	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the □	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ • If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ • If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: • • INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: □	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: □ INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: □ INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □	Initial &
Decision • If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ • If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ • If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: • INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: • INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □ • There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: • INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □ • There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating restoration of hepatic synthetic function) □	Initial &
Decision • If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ • If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ • If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: • • INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: • INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □ • There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating	Initial &
Decision • If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) • If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team • If extended or restarted acetylcysteine is indicated follow advice below • If extended treatment is required if: • INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). Discontinue extended treatment when: • INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □ • There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating restoration of hepatic synthetic function) Extended or restarted treatment with acetylcysteine was required	Initial &
Decision If further treatment or blood sampling is not required go to 'Subsequent Management & Discharge' (page 9) □ If monitoring of renal function is required, obtain blood samples 12 hours later and review by medical team □ If extended or restarted acetylcysteine is indicated follow advice below □ Extended treatment is required if: INR is greater than 1.3 OR the ALT has increased further on review of discharge (20hour) bloods □ • Continue acetylcysteine at the dose and infusion rate used in the 2 nd treatment bag □ • Recheck U&Es, LFTs, FBC, VBG/CBG with lactate and INR every 10 hours to assess the course of liver injury (2 hours before the end of each extended bag). □ Discontinue extended treatment when: • INR 1.3 or less; OR falling towards normal on two consecutive blood tests, and less than 3 □ • There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating restoration of hepatic synthetic function) □	Initial &

Patients < 16 years PARACETAMOL OVERDOSE -more than 24 HOURS Date: Clinical area: ED Ward STAGE 4 - SUBSEQUENT MANAGEMENT & DISCH	ADDRESSOGRAPH, or Name: DoB: Hospital number: CHI: ARGE	
 Criteria for discharge Treatment with acetylcysteine tolerated Patient eating and drinking. Seen by CAMHS/Psychiatry team member Comment 	N/A □ Yes □ No □ Yes □No □ N/A □ Yes □ No□	Initial/time
 Treatment complete Discharge advice given, including paracetamol para TOXBASE[®]) □ Comment		Initial/time
Follow-up Has follow-up been arranged? Comment 	N/A □ Yes □ No □	Initial/time
Notes Medical follow-up arrangements are not normally re	equired if blood results are within acceptable	range

Г

VARIANCES: <u>all</u> staff to identify & record variances. Types of Variance - break down into types: A - Patient/Relative, B - Clinician, C - Hospital System, D - Community/External.

Record of Variance							
Date	Time	Description of issue	Reason	Action	Initials	Var. code	
EXAMPLE 28.09.15	00.15	Flushing	Reaction to acetylcysteine	Infusion stopped for 30 minutes. Chlorphenamine administered	BS	А	